Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder
NCT ID: NCT06975514
Last Updated: 2025-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
60 participants
INTERVENTIONAL
2025-03-25
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder
NCT05525637
Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder
NCT06680505
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants
NCT06673927
PK/PD Study of YZJ-1139
NCT06685341
A Study of Zolpidem Tartrate Sublingual Tablet in Adult Patients With Insomnia
NCT00466193
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
YZJ-1139 group
YZJ-1139
YZJ-1139 20mg tablets, once daily in the evening
Zolpidem group
Zolpidem
Zolpidem 10mg tablets, once daily in the evening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
YZJ-1139
YZJ-1139 20mg tablets, once daily in the evening
Zolpidem
Zolpidem 10mg tablets, once daily in the evening
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Meet the clinical diagnostic criteria for insomnia disorder as defined in ICSD-3 criteria.
3. sTSO ≥ 30 min for at least 3 nights per week and/or sWASO ≥ 60 min for at least 3 nights per week within 4 weeks prior to screening.
4. Able to recognize 26 English letters and MMSE score indicats no cognitive impairment.
5. During the run-in period and on Day 1 of the treatment period, sTSO ≥ 30 min for at least 3 nights in the last 7 sleep diaries and/or sWASO ≥ 60 min for at least 3 nights out of 7 nights as confirmed by the sleep diary prior to PSG monitoring.
6. PSG results for 2 consecutive nights during the run-in period should meet the following conditions:
1. The mean LPS ≥ 30 min for 2 nights and ≥ 20 min for any one night; And/or the mean WASO ≥ 60 min for 2 nights, and ≥ 45 min either night.
2. The mean SE ≤ 85% for 2nights, with the SE ≤ 87.5% for both nights .
7. ISI score ≥ 15 at screening and on Day 1 of the treatment period .
8. Have a bedtime between 9 p.m. and 1 a.m., wake up between 5 a.m. and 10 a.m., and stay in bed for 6.5 to 9 hours for at least 5 nights in the last 7 sleep diaries as confirmed by the sleep diary prior to PSG monitoring during the run-in period and on Day 1 of the treatment period.
9. Reproductive-age male and female participants must agree to use effective contraceptive measures from the screening visit through at least 30 days after the last dose of double-blind study treatment, and must not be planning to become pregnant or donate sperm/eggs during this period.
10. Understand the study procedures and contents, voluntarily participate in the clinical study and sign the written Informed Consent Form, have good compliance during participation in the study, and are willing to attend the visits.
Exclusion Criteria
2. Have serious endocrine diseases, hematological diseases, cardiovascular and cerebrovascular diseases, gastrointestinal diseases, liver and kidney diseases, autoimmune diseases, impaired respiratory function or other related diseases, or have other medical history that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
3. Have insomnia disorder due to other causes such as chronic pain, headache, eczema, neurodermatitis, allergic rhinitis, and serious dermatitis (difficulty sleeping due to physical reasons, difficulty falling asleep due to medical reasons).
4. Current or previous history of psychiatric or neurological disease such as epilepsy, schizophrenia, bipolar mental disorder, neurodevelopmental retardation, and cognitive disorder, or previous history of other mental illness that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
5. Previous history of sleep-related respiratory disorders including obstructive sleep apnea (with or without continuous positive airway pressure \[CPAP\] therapy), periodic limb movement disorder, myasthenia gravis, restless legs syndrome, circadian rhythm sleep disturbances, narcolepsy or other sleep disorders: subjects with restless legs syndrome which is diagnosed by relevant diagnostic and treatment guidelines should be excluded. Those who have been cured of the above diseases can be enrolled.
6. Have previous complex sleep behaviors, such as sleep driving, sleep eating, and sleep phone calls.
7. Have nocturia increased caused by urinary tract infection, urinary tract injury or prostatic disorder.
8. Hyperthyroidism.
9. History of alcohol abuse (defined as regular daily alcohol consumption exceeding the following criteria: approximately 720 mL of beer, or 240 mL of wine, or 60 mL of liquor) within the past 6 months.
10. Regular daily consumption of excessive tea and coffee drinks (defined as consumption of \> 4 cups of caffeinated beverages or \> 400 mg of caffeine per day), or daily habituation to drinking caffeinated beverages beyond 18:00.
12. Have any lifestyle that interferes with the study process or may interfere with sleep: for example, there will be travels across 3 or more time zones (mainland China is considered as 1 time zone) within the next 2 weeks or during the study period, or there will be shift work (night and daytime shift).
13. History of drug abuse within the past 2 years, or positive urine drug screening for any indicator; history of drug taking or addiction, which is known through questioning.
14. Have received any hypnotics, antidepressants, antipsychotic drugs, anticholinergics, memory-enhancing drugs, antihistamines, centrally acting analgesics, centrally acting muscle relaxants, central nervous system stimulants, CYP3A inducers, CYP3A inhibitors, traditional Chinese medicines and traditional Chinese medicinal products with sleep-improving effects, or any other therapies for insomnia disorder within 1 week prior to the run-in period or within 5 half-lives of the investigational product, whichever is longer.
15. Plan to undergo surgery during the study.
16. Depression: Hamilton Depression Scale (HAMD) score ≥ 18; anxiety: Hamilton Anxiety Scale (HAMA) score ≥ 14.
17. Suicidal ideation with or without plan at screening or within 6 months prior to screening (score ≥ 3 on item 3 \[suicide\] of HAMD, or select "Yes" on item 3, 4 or 5 of suicidal ideation subscale of C-SSRS), or have any suicidal behavior in the past 10 years (as assessed by the suicidal ideation subscale of C-SSRS).
18. ECG at screening shows QTcF interval prolongation (QTcF \> 450 ms, QTcF=QT/(RR\^0.33)).
19. AST or ALT \> 2 × the upper limit of normal (ULN), or Cr \> 1.5 × ULN.
20. Known to be human immunodeficiency virus (HIV) antibody positive at screening.
21. Apnea-hypopnea index \[AHI\] or periodic limb movement index \[PLMI\] \> 10 times/hour detected by PSG monitoring during the run-in period.
22. Unable to avoid vaccination within 1 month prior to screening.
23. Enrolled in another clinical trial and used any investigational drug within 1 month or 5 half-lives (whichever is longer) prior to the run-in period, or participation in another investigational trial at the same time during this trial.
24. Previously participated in any clinical trial of YZJ-1139; or treated with other orexin receptor antagonists of appropriate amount and sufficient duration and who, in the opinion of the investigator, have failed treatment due to efficacy or safety.
25. Pregnant or lactating women.
26. Have other conditions that make the subject unsuitable for participation in the clinical study in the opinion of the investigator.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, , China
ChengDu Second People's Hospital
Chengdu, , China
ChongQing Traditional Chinese Medicine Hospital
Chongqing, , China
Deyang People's Hospital
Deyang, , China
The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital)
Guangzhou, , China
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
Jinan, , China
The Second Affiliated Hospital Of NanChang University
Nanchang, , China
The First Affiliated Hospital of Ningbo University
Ningbo, , China
ShengJing Hospital Of China Medical University
Shenyang, , China
The Third Hospital of Hebei Medical University
Shijiazhuang, , China
SuZhou GuangJi Hospital
Suzhou, , China
The Second Affiliated Hospital of Soochow University
Suzhou, , China
Tianjin Anding Hospital
Tianjin, , China
Wuhan No.1 Hospital
Wuhan, , China
Yan'an University Xianyang Hospital
Yan’an, , China
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YZJ-1139-3-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.